OptimaCure · raw details

OptimaCure provides personalized treatment for patients with cancer by repositioning failed cancer drugs. The companys solution employs multiple robust screening approaches that indicate the most appropriate and optimal drug combinations for treating individual cancer patients. The companys process identifies the patients most likely to respond positively to the suggested drug treatment. It can also identify broader applications for the repositioned cancer drugs in treating additional indications. By combining multiple technologies (e.g. in vivo, in vitro, and in silico), OptimaCures proprietary approach enhances the understanding of the mode of action of the selected failed drugs and their combination and repositions them toward the appropriate cancer patients. OptimaCure is a subsidiary of Goldman Hirsh Partners.